Group 2 innate lymphoid cells in nasal polyposis

Area of Science:

• Immunology
• Otorhinolaryngology
• Molecular Biology

Background:

• Chronic rhinosinusitis with nasal polyps (CRSwNP) involves persistent type 2 inflammation in the sinuses.
• Group 2 innate lymphoid cells (ILC2s) are critical immune cells that produce type 2 cytokines (IL-4, IL-5, IL-13).
• Emerging evidence highlights the significant role of ILC2s in the development of CRSwNP.

Purpose of the Study:

• To review the literature on the presence, function, and activation of ILC2s in CRSwNP.
• To understand the contribution of ILC2s to the pathogenesis of CRSwNP.
• To identify potential therapeutic targets within ILC2-mediated inflammatory pathways.

Main Methods:

• Literature review of published studies.
• PubMed database searches for relevant research.
• Inclusion of studies detailing ILC2 presence, function, and activation in CRSwNP.

Main Results:

• Human ILC2s were first discovered in nasal polyps (NPs), which show significantly elevated ILC2 numbers.
• ILC2s in NPs are highly activated, producing type 2 cytokines in vivo.
• Elevated levels of ILC2 activators (e.g., TSLP, PGD2, IL-4, IL-13) and specific transcriptional pathways (e.g., NF-κB, NFAT, STAT5, STAT6) are observed in NPs.

Conclusions:

• ILC2-driven type 2 inflammation is central to CRSwNP pathogenesis.
• Modulating upstream ILC2 activators and downstream cytokine production offers a promising therapeutic strategy for CRSwNP.
• Targeting ILC2 pathways may lead to improved clinical outcomes for patients with CRSwNP.